Methylene blue has had a strange journey: a Victorian textile dye, one of the first synthetic drugs ever used against malaria, a hospital treatment for a rare blood disorder, and now a fixture of biohacking forums where it is sold as a memory booster. The gap between what the research actually shows and what the marketing claims is wide, so this guide sticks to what published human studies have found.

My answer is: there is early human evidence that a single low dose of methylene blue can produce a small, measurable improvement in memory retrieval in healthy adults, but there is no good evidence that taking it regularly improves memory in everyday life, and it carries real risks – including a dangerous interaction with common antidepressants. For most people, this is not a supplement to self-experiment with.

What methylene blue actually is

Methylene blue (methylthioninium chloride) is a prescription medicine, not a dietary supplement. Its one established medical use is treating acquired methaemoglobinaemia, a rare blood disorder where red blood cells cannot carry oxygen properly. The prescription product (ProvayBlue in the US) is approved for that use only, and the compound sits on the World Health Organization’s Model List of Essential Medicines for the same reason.

Every use related to memory, focus, or “brain health” is off-label. No regulator has approved methylene blue as a cognitive enhancer, and there is no agreed safe or effective dose for that purpose.

Its scientific appeal comes from its chemistry. It crosses the blood-brain barrier easily, and inside cells it can act as an alternative electron carrier in mitochondria, the structures that produce cellular energy. Because the brain uses roughly 20% of the body’s energy, researchers have wondered for decades whether supporting mitochondrial function could support memory.

What the human studies found

The most cited piece of evidence is a small randomised, double-blind, placebo-controlled study from 2016. Healthy adults received a single low dose of methylene blue or placebo, then completed memory tasks inside an MRI scanner. The methylene blue group recalled about 7% more information correctly, and their scans showed increased activity in brain regions involved in attention and short-term memory (Rodriguez et al., 2016). A related study from the same group found that a single dose altered functional connectivity – the coordination between brain regions – at rest (Rodriguez et al., 2016b).

These are genuine findings from real trials, which puts them ahead of most supplement claims. But it is worth being precise about what they are: single-dose studies in small groups of healthy volunteers, measured over hours. They do not tell us whether daily use helps, whether benefits persist, or whether the effect matters for real-life memory tasks like remembering names or appointments.

Two other human findings are worth knowing:

• Fear extinction. In a randomised trial of adults with claustrophobia, a dose of methylene blue given after exposure therapy improved retention of the therapy’s effect and memory a month later – but only when the exposure session had gone well (Telch et al., 2014). Interesting, but a very specific clinical context.
• Mood disorders. Small controlled trials decades ago and more recently suggest methylene blue can improve depressive symptoms, including residual symptoms in bipolar disorder at a medically supervised dose of 195 mg daily (Naylor et al., 1987; Alda et al., 2017). These used prescription-grade dosing under supervision – they are not evidence for supplement use.

The Alzheimer’s story, honestly told

Methylene blue inhibits the clumping of tau protein in the laboratory, which made a derivative (LMTM) a serious candidate for Alzheimer’s disease. Then came the decisive test: a phase 3 randomised controlled trial in nearly 900 patients with mild to moderate Alzheimer’s. LMTM did not work – it failed to show benefit on its primary measures of cognition and daily function (Gauthier et al., 2016). Claims that methylene blue “fights Alzheimer’s” rest on laboratory and animal work that the largest human trial did not confirm.

Why dose changes everything

Methylene blue shows a hormetic response: low and high doses can produce different, even opposite, effects. At low doses it may support mitochondrial efficiency; at higher doses it can increase oxidative stress. There is no established “nootropic” dose, and dosing advice measured in “drops” is meaningless because product concentrations vary. Any decision about dose belongs with a doctor using a pharmaceutical-grade product, not a forum.

The risks that matter

Antidepressants and serotonin syndrome. This is the big one. Methylene blue is a potent monoamine oxidase-A (MAO-A) inhibitor. Combined with SSRIs, SNRIs, MAOIs, certain opioids, or other serotonergic medicines, it can trigger serotonin syndrome, a potentially fatal reaction. The ProvayBlue label carries the FDA’s strongest warning – a boxed warning – about exactly this. If you take any antidepressant, do not take methylene blue unless your prescriber explicitly says otherwise.

G6PD deficiency. In people with this inherited condition (more common in people of African, Mediterranean, Middle Eastern and South Asian ancestry), methylene blue can cause severe breakdown of red blood cells. It is a formal contraindication. A simple blood test can check your status.

Pregnancy and breastfeeding. Methylene blue is not recommended; the potential risks to the baby are not ruled out.

Ordinary side effects. Headache, nausea, dizziness, sweating, and a harmless blue-green colour to urine are the common ones. It can also distort pulse oximeter readings and some lab tests, so tell healthcare staff if you have taken it.

Product quality. Much of the methylene blue sold online is aquarium or industrial grade, which can contain impurities never assessed for human use. Pharmaceutical-grade material exists, but in the UK methylene blue is not licensed as a food supplement, so products marketed for brain health sit outside the usual quality protections.

The bottom line

Methylene blue is one of the more genuinely interesting compounds in the nootropic world: it crosses into the brain, it has a plausible mechanism, and small human trials have measured real short-term effects on memory retrieval. But the evidence stops there. There are no long-term safety data for daily use, no approved cognitive dose, a failed phase 3 Alzheimer’s trial behind it, and a serious interaction risk with antidepressants that many buyers will be taking.

If you are curious about it, the right next step is a conversation with your GP – particularly if you take any medication – rather than a bottle from the internet. And the foundations that actually have decades of evidence behind them (sleep, exercise, stress management, and treating any real deficiency) will do more for your memory than any blue dye.

Important note: This article is for general information only and is not medical advice. Methylene blue is a prescription medicine with serious interaction risks. Always talk to your doctor before starting, stopping, or combining any supplement or medicine, especially if you take antidepressants or other prescription medication.

References

1. Rodriguez P, Zhou W, Barrett DW, et al. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology. 2016;281(2):516-526. pubmed.ncbi.nlm.nih.gov/27351678
2. Rodriguez P, Zhou W, Barrett DW, et al. Methylene blue modulates functional connectivity in the human brain. Brain Imaging and Behavior. 2017;11(3):640-648. pubmed.ncbi.nlm.nih.gov/26961091
3. Telch MJ, Bruchey AK, Zaizar E, et al. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. American Journal of Psychiatry. 2014;171(10):1091-1098. pubmed.ncbi.nlm.nih.gov/25018057
4. Naylor GJ, Smith AHW, Connelly P. A controlled trial of methylene blue in severe depressive illness. Biological Psychiatry. 1987;22(5):657-659. doi.org/10.1016/0006-3223(87)90194-6
5. Alda M, McKinnon M, Blagdon R, et al. Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. The British Journal of Psychiatry. 2017;210(1):54-60. pubmed.ncbi.nlm.nih.gov/27284082
6. Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. The Lancet. 2016;388(10062):2873-2884. doi.org/10.1016/S0140-6736(16)31275-2
7. PROVAYBLUE (methylene blue) injection – prescribing information, including boxed warning on serotonin syndrome. DailyMed, US National Library of Medicine. dailymed.nlm.nih.gov
8. Methylthioninium chloride (methylene blue) – WHO Model List of Essential Medicines. list.essentialmeds.org